Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.
Two Macaca fascicularis with preexisting immunity to vaccinia virus were immunized twice with recombinant vaccinia virus expressing SIVmne gp160. Their SIV-specific antibody responses were lower than that of vaccinia-naive animals immunized similarly. Upon repeated boosting with gp160, the SIV-specific antibody titers in vaccinia-primed animals reached similar levels as vaccinia-naive animals and with comparable neutralizing titers. Both animals were protected against repeated intravenous challenge with low-dose SIVmne E11S. These results are significant because SIVmne E11S infection in M. fascicularis is pathogenic and leads to AIDS-like diseases.
Hu
S L
SL
Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, WA 98121.
Stallard
V
V
Abrams
K
K
Barber
G N
GN
Kuller
L
L
Langlois
A J
AJ
Morton
W R
WR
Benveniste
R E
RE
D000818:Animals; D001483:Base Sequence; D004279:DNA, Viral / Q000235:genetics; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology*; D007114:Immunization; D007117:Immunization, Secondary; D008252:Macaca fascicularis; D008969:Molecular Sequence Data; D016097:Simian Acquired Immunodeficiency Syndrome / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000494:pharmacology; D014616:Vaccinia virus / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000494:pharmacology*
D004279:DNA, Viral; D015686:Gene Products, env; D014614:Vaccines, Synthetic; D014765:Viral Vaccines